Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms ...Middle East

PR Newswire - News
Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms

Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout six-month follow-up period Immune-conditioning with short steroid course supported higher levels of transgene expression Results will guide design of Phase 2 study and discussion with regulatory...

    Read More Details
    Finally We wish PressBee provided you with enough information of ( Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms )

    Apple Storegoogle play

    Also on site :